감염성 호흡기질환 진단 시장 규모, 점유율, 동향 분석 : 제품별, 샘플별, 용도별, 기술별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Infectious Respiratory Disease Diagnostics Market Growth & Trends:

The global infectious respiratory disease diagnostics market size is anticipated to reach USD 73.56 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 5.3% from 2025 to 2030. The decline in market size is majorly attributed to the decline in COVID-19 testing. However, the market without the impact of COVID-19 is expected to grow over the forecast years. The growth can be attributed to an increase in the prevalence of infectious respiratory diseases and initiatives taken by governments & nonprofit organizations to introduce novel & innovative products to address the increasing demand. For instance, the global investment in tuberculosis R&D reached USD 915 million, and around USD 401 million was spent by the U.S. government on TB research in 2020.

During the forecast period, the global industry is expected to be driven by the rising incidence of infectious respiratory disorders, such as tuberculosis, RSV, and influenza. According to the UN, pneumonia affects around 4.2 million people every year. Key players are developing innovative techniques to improve production for meeting the growing demand in diagnostics and consumables for the diagnosis of infectious diseases. For instance, OPT Industries Inc. has introduced InstaSwab by utilizing the 3D printing system to address supply shortages of sample collection kits due to the COVID-19 pandemic. These swabs are made of woven lattices to absorb and release more fluid than conventional swabs. Companies are advancing their diagnosis products by using new techniques to gain target-specific and accurate results.

Canon Inc. announced the development of a built-in AEC assistance for digital X-rays in March 2021. The X-ray image sensor enables users to perform picture production and real-time detection of images corresponding to emitted X-rays. Furthermore, in May 2021, the University of California developed an ultrasensitive molecular test to identify the presence of SARS-CoV-2 and influenza A antigens using chip technology. In addition, companies are also launching multiplex tests for the simultaneous diagnosis of RSV, influenza, and COVID-19 respiratory diseases. RT-PCR tests are considered the gold standard for the diagnosis of COVID-19 in patients. However, high prices associated with molecular tests are one of the major factors impeding this market.

The lack of comparable products is another reason for hiked prices. This problem is further compounded by the significant variations in prices for different applications of each molecular diagnostic product. Companies are adopting strategies, such as new product launches and partnerships, to increase the penetration of infectious respiratory disease diagnostics products. For instance, in August 2021, Thermo Fisher Scientific Inc. received EUA for the introduction of two COVID-19 diagnostic products, TaqPath COVID-19 RNase P Combo Kit and TaqPath COVID-19 Fast PCR Combo Kit, in the U.S. market.

Infectious Respiratory Disease Diagnostics Market Report Highlights:

• The consumables segment dominated the market and accounted for the largest revenue share of 64.3% in 2024. Technological advancements in diagnostic devices have resulted in more sophisticated testing methods, necessitating specialized consumables.
• The COVID-19 segment dominated the global market in 2024, accounting for 43.8% of the revenue. Increased COVID-19 variants, product approvals, and heightened research and development efforts drove this dominance.
• North America infectious respiratory disease diagnostics market dominated the overall global market and accounted for 41.85% of revenue share in 2024.
• Tuberculosis is expected to exhibit the fastest CAGR over the forecast period owing to increasing government focus and R&D funding for the development of diagnostics
• Asia Pacific is expected to experience the fastest growth over the forecast period owing to an increase in penetration of IVD products, rise in disposable income, and high prevalence of tuberculosis in underdeveloped countries

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Technology
  • 1.2.2. Sample
  • 1.2.3. Product
  • 1.2.4. End Use
  • 1.2.5. Application
  • 1.2.6. Regional Scope
  • 1.2.7. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Infectious Respiratory Disease Diagnostics Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. High Prevalence Of Infectious Respiratory Diseases Globally
    • 3.2.1.2. Technological Advancement In Respiratory Disease Testing
    • 3.2.1.3. Rising R&D Investments In Respiratory Disease Testing
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High Prices Of Diagnostic Products
    • 3.2.2.2. Presence Of Ambiguous Regulatory Framework
• 3.3. Infectious Respiratory Disease Diagnostics Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Infectious Respiratory Disease Diagnostics Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Infectious Respiratory Disease Diagnostics Market: Product Movement Analysis
• 4.3. Infectious Respiratory Disease Diagnostics Market by Product Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Instruments
  • 4.5.1. Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.2. Imaging Tests
    • 4.5.2.1. Imaging Tests Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.3. Respiratory Measurement Devices
    • 4.5.3.1. Respiratory Measurement Devices Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5.4. Other Instruments
    • 4.5.4.1. Other Instruments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Consumables
  • 4.6.1. Consumables Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Services
  • 4.7.1. Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Infectious Respiratory Disease Diagnostics Market: Sample Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Infectious Respiratory Disease Diagnostics Market: Sample Movement Analysis
• 5.3. Infectious Respiratory Disease Diagnostics Market by Sample Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Saliva
  • 5.5.1. Saliva Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Nasopharyngeal Swabs
  • 5.6.1. Nasopharyngeal Swabs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Anterior Nasal Region
  • 5.7.1. Anterior Nasal Region Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Blood
  • 5.8.1. Blood Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Infectious Respiratory Disease Diagnostics Market: Technology Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Infectious Respiratory Disease Diagnostics Market: Technology Movement Analysis
• 6.3. Infectious Respiratory Disease Diagnostics Market by Technology Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Immunoassay
  • 6.5.1. Immunoassay Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Molecular Diagnostics
  • 6.6.1. Molecular Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Microbiology
  • 6.7.1. Microbiology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.8. Other Technologies
  • 6.8.1. Other Technologies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Infectious Respiratory Disease Diagnostics Market: Application Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Infectious Respiratory Disease Diagnostics Market: Application Movement Analysis
• 7.3. Infectious Respiratory Disease Diagnostics Market by Application Outlook (USD Million)
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 7.5. COVID-19
  • 7.5.1. COVID-19 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Influenza
  • 7.6.1. Influenza Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Respiratory Syncytial Virus
  • 7.7.1. Respiratory Syncytial Virus Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Tuberculosis
  • 7.8.1. Tuberculosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.9. Streptococcus Testing
  • 7.9.1. Streptococcus Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.10. Other Respiratory Disease Testing
  • 7.10.1. Other Respiratory Disease Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Infectious Respiratory Disease Diagnostics Market: End Use Estimates & Trend Analysis

• 8.1. Segment Dashboard
• 8.2. Infectious Respiratory Disease Diagnostics Market: End Use Movement Analysis
• 8.3. Infectious Respiratory Disease Diagnostics Market by End Use Outlook (USD Million)
• 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 8.5. Hospitals
  • 8.5.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Diagnostic Laboratories
  • 8.6.1. Diagnostic Laboratories Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.7. Pharmaceutical & Biotechnology Companies
  • 8.7.1. Pharmaceutical & Biotechnology Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.8. Physician Offices
  • 8.8.1. Physician Offices Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.9. Other End-Users
  • 8.9.1. Other End-Users Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Infectious Respiratory Disease Diagnostics Market: Regional Estimates & Trend Analysis

• 9.1. Regional Dashboard
• 9.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 9.3. North America
  • 9.3.1. U.S.
    • 9.3.1.1. Key country dynamics
    • 9.3.1.2. Regulatory framework/ reimbursement structure
    • 9.3.1.3. Competitive scenario
    • 9.3.1.4. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.3.2. Canada
    • 9.3.2.1. Key country dynamics
    • 9.3.2.2. Regulatory framework/ reimbursement structure
    • 9.3.2.3. Competitive scenario
    • 9.3.2.4. Canada market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.3.3. Mexico
    • 9.3.3.1. Key country dynamics
    • 9.3.3.2. Regulatory framework/ reimbursement structure
    • 9.3.3.3. Competitive scenario
    • 9.3.3.4. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
• 9.4. Europe
  • 9.4.1. UK
    • 9.4.1.1. Key country dynamics
    • 9.4.1.2. Regulatory framework/ reimbursement structure
    • 9.4.1.3. Competitive scenario
    • 9.4.1.4. UK market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.4.2. Germany
    • 9.4.2.1. Key country dynamics
    • 9.4.2.2. Regulatory framework/ reimbursement structure
    • 9.4.2.3. Competitive scenario
    • 9.4.2.4. Germany market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.4.3. France
    • 9.4.3.1. Key country dynamics
    • 9.4.3.2. Regulatory framework/ reimbursement structure
    • 9.4.3.3. Competitive scenario
    • 9.4.3.4. France market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.4.4. Italy
    • 9.4.4.1. Key country dynamics
    • 9.4.4.2. Regulatory framework/ reimbursement structure
    • 9.4.4.3. Competitive scenario
    • 9.4.4.4. Italy market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.4.5. Spain
    • 9.4.5.1. Key country dynamics
    • 9.4.5.2. Regulatory framework/ reimbursement structure
    • 9.4.5.3. Competitive scenario
    • 9.4.5.4. Spain market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.4.6. Norway
    • 9.4.6.1. Key country dynamics
    • 9.4.6.2. Regulatory framework/ reimbursement structure
    • 9.4.6.3. Competitive scenario
    • 9.4.6.4. Norway market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.4.7. Sweden
    • 9.4.7.1. Key country dynamics
    • 9.4.7.2. Regulatory framework/ reimbursement structure
    • 9.4.7.3. Competitive scenario
    • 9.4.7.4. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.4.8. Denmark
    • 9.4.8.1. Key country dynamics
    • 9.4.8.2. Regulatory framework/ reimbursement structure
    • 9.4.8.3. Competitive scenario
    • 9.4.8.4. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
• 9.5. Asia Pacific
  • 9.5.1. Japan
    • 9.5.1.1. Key country dynamics
    • 9.5.1.2. Regulatory framework/ reimbursement structure
    • 9.5.1.3. Competitive scenario
    • 9.5.1.4. Japan market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.5.2. China
    • 9.5.2.1. Key country dynamics
    • 9.5.2.2. Regulatory framework/ reimbursement structure
    • 9.5.2.3. Competitive scenario
    • 9.5.2.4. China market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.5.3. India
    • 9.5.3.1. Key country dynamics
    • 9.5.3.2. Regulatory framework/ reimbursement structure
    • 9.5.3.3. Competitive scenario
    • 9.5.3.4. India market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.5.4. Australia
    • 9.5.4.1. Key country dynamics
    • 9.5.4.2. Regulatory framework/ reimbursement structure
    • 9.5.4.3. Competitive scenario
    • 9.5.4.4. Australia market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.5.5. South Korea
    • 9.5.5.1. Key country dynamics
    • 9.5.5.2. Regulatory framework/ reimbursement structure
    • 9.5.5.3. Competitive scenario
    • 9.5.5.4. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.5.6. Thailand
    • 9.5.6.1. Key country dynamics
    • 9.5.6.2. Regulatory framework/ reimbursement structure
    • 9.5.6.3. Competitive scenario
    • 9.5.6.4. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
• 9.6. Latin America
  • 9.6.1. Brazil
    • 9.6.1.1. Key country dynamics
    • 9.6.1.2. Regulatory framework/ reimbursement structure
    • 9.6.1.3. Competitive scenario
    • 9.6.1.4. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.6.2. Argentina
    • 9.6.2.1. Key country dynamics
    • 9.6.2.2. Regulatory framework/ reimbursement structure
    • 9.6.2.3. Competitive scenario
    • 9.6.2.4. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
• 9.7. MEA
  • 9.7.1. South Africa
    • 9.7.1.1. Key country dynamics
    • 9.7.1.2. Regulatory framework/ reimbursement structure
    • 9.7.1.3. Competitive scenario
    • 9.7.1.4. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.7.2. Saudi Arabia
    • 9.7.2.1. Key country dynamics
    • 9.7.2.2. Regulatory framework/ reimbursement structure
    • 9.7.2.3. Competitive scenario
    • 9.7.2.4. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.7.3. UAE
    • 9.7.3.1. Key country dynamics
    • 9.7.3.2. Regulatory framework/ reimbursement structure
    • 9.7.3.3. Competitive scenario
    • 9.7.3.4. UAE market estimates and forecasts 2018 - 2030 (USD Million)
  • 9.7.4. Kuwait
    • 9.7.4.1. Key country dynamics
    • 9.7.4.2. Regulatory framework/ reimbursement structure
    • 9.7.4.3. Competitive scenario
    • 9.7.4.4. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Market Participant Categorization
• 10.2. Recent Developments & Impact Analysis by Key Market Participants
• 10.3. Company Market Share Analysis, 2024
• 10.4. Key Company Profiles
  • 10.4.1. ABBOTT
    • 10.4.1.1. Company overview
    • 10.4.1.2. Financial performance
    • 10.4.1.3. Product benchmarking
    • 10.4.1.4. Strategic initiatives
  • 10.4.2. F. Hoffmann - La Roche Ltd
    • 10.4.2.1. Company overview
    • 10.4.2.2. Financial performance
    • 10.4.2.3. Product benchmarking
    • 10.4.2.4. Strategic initiatives
  • 10.4.3. THERMO FISHER SCIENTIFIC, INC.
    • 10.4.3.1. Company overview
    • 10.4.3.2. Financial performance
    • 10.4.3.3. Product benchmarking
    • 10.4.3.4. Strategic initiatives
  • 10.4.4. KONINKLIJKE PHILIPS N.V.
    • 10.4.4.1. Company overview
    • 10.4.4.2. Financial performance
    • 10.4.4.3. Product benchmarking
    • 10.4.4.4. Strategic initiatives
  • 10.4.5. BIOMERIEUX SA
    • 10.4.5.1. Company overview
    • 10.4.5.2. Financial performance
    • 10.4.5.3. Product benchmarking
    • 10.4.5.4. Strategic initiatives
  • 10.4.6. BIO-RAD LABORATORIES, INC.
    • 10.4.6.1. Company overview
    • 10.4.6.2. Financial performance
    • 10.4.6.3. Product benchmarking
    • 10.4.6.4. Strategic initiatives
  • 10.4.7. QUIDEL CORPORATION
    • 10.4.7.1. Company overview
    • 10.4.7.2. Financial performance
    • 10.4.7.3. Product benchmarking
    • 10.4.7.4. Strategic initiatives
  • 10.4.8. CEPHEID
    • 10.4.8.1. Company overview
    • 10.4.8.2. Financial performance
    • 10.4.8.3. Product benchmarking
    • 10.4.8.4. Strategic initiatives
  • 10.4.9. QIAGEN
    • 10.4.9.1. Company overview
    • 10.4.9.2. Financial performance
    • 10.4.9.3. Product benchmarking
    • 10.4.9.4. Strategic initiatives
  • 10.4.10. SIEMENS HEALTHCARE GMBH
    • 10.4.10.1. Company overview
    • 10.4.10.2. Financial performance
    • 10.4.10.3. Product benchmarking
    • 10.4.10.4. Strategic initiatives